Lenient Rate Control Versus Strict Rate Control for Atrial Fibrillation. The Danish Atrial Fibrillation Randomised Clinical Trial

NARecruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

March 31, 2021

Primary Completion Date

March 2, 2026

Study Completion Date

March 2, 2026

Conditions
Atrial Fibrillation, PersistentAtrial Fibrillation ChronicAtrial Fibrillation
Interventions
OTHER

Rate control

Treatment will be provided according to current guidelines and as such the algorithm for treatment will be differentiated based on the status of left ventricular ejection fraction. For participants with reduced left ventricular ejection fraction, beta-blockers (metoprolol and bisoprolol) will be the primary therapy. Secondary therapies may include digoxin or amiodarone. For participants with preserved left ventricular ejection fraction, the primary therapy will be beta-blockers (metoprolol and bisoprolol) or non-dihydropyridine calcium-channel blockers (verapamil) with secondary therapy consisting of digoxin or amiodarone. Pacing therapies, alone or with atrioventricular node ablation, are utilised as indicated in the view of the treating physician.

Trial Locations (4)

2650

NOT_YET_RECRUITING

Hvidovre University Hospital, Hvidovre

4000

NOT_YET_RECRUITING

Zealand University Hospital - Roskilde, Roskilde

4300

RECRUITING

Holbæk Hospital, Holbæk

5000

NOT_YET_RECRUITING

Odense University Hospital, Odense

All Listed Sponsors
collaborator

Odense University Hospital

OTHER

collaborator

Hvidovre University Hospital

OTHER

collaborator

Zealand University Hospital

OTHER

lead

Holbaek Sygehus

OTHER